Orexo welcomes increased access to treatment for patients with opioid dependence in the US

Uppsala, Sweden – July 7, 2016 – Orexo AB applauds the Administration’s
announcement yesterday to increase access to the treatment of opioid dependence
in the US, by increasing the cap on the number of patients that can be treated
by physicians from 100 to 275, starting 30 days after publication in the Federal
Register. Additionally, we commend the strong bipartisan Congressional support
of this announcement. We look forward to Congress passing additional legislation
further supporting increased access to appropriate patient care.

More than 5 million US citizens are misusing opioids and at least 2 million are
opioid dependent. Today about 640,000 patients are in treatment with
buprenorphine. Many struggle to find a qualified physician due to the patient
cap which has been a significant hurdle in many regions of the US. In several
instances, the lack of access to a qualified physician has led to a vicious
cycle forcing patients to obtain their treatment on the street in a drug abusing
environment perpetuating the risk of continued addiction.

Orexo strongly believes that medication assisted treatment with buprenorphine
containing products, prescribed by a qualified physician should be used as part
of a comprehensive treatment plan, which includes counseling and psychosocial
support. With the initiative announced, opioid dependence treatment takes an
important step towards open and affordable access to treatment in an appropriate
clinical setting.

“I am encouraged by the initiative announced, which will be a significant change
for many patients suffering from opioid dependence and save lives. For Orexo and
our product Zubsolv® this change will be important for our continued sales and
market share growth. I am proud of the incredible efforts our US team has made
in Washington DC during the last 12 months to support the legislators and
government with information and knowledge leading to this game changing decision
for patients, physicians and for Orexo” said Nikolaj Sørensen, CEO and President
of Orexo AB.

For more information please contact:

Orexo AB (publ.)
Nikolaj Sørensen, CEO and President
Tel: +46 (0)18 780 88 00
email: ir@orexo.com

About Orexo

Orexo is a specialty pharmaceutical company commercializing its proprietary
product Zubsolv® for treatment of opioid dependence in the US. Zubsolv is an
advanced formulation of buprenorphine and naloxone using Orexo’s unique
knowledge and expertise in sublingual drug delivery. R&D is focusing on
reformulation of known substances to new improved products that meet great unmet
medical needs by using its patented proprietary technologies. Orexo’s share is
listed on Nasdaq Stockholm Exchange Mid Cap (STO:ORX) and is available as ADRs
on OTCQX (ORXOY) in the US. Orexo’s global headquarters and R&D are based in
Uppsala, Sweden.

For more information about Orexo and Zubsolv, please visit www.orexo.com and
www.zubsolv.com.

This is information is information that Orexo AB is obliged to make public
pursuant to the EU Market Abuse Regulation. The information was submitted for
publication, through the agency of the contact persons set out above, at 8.00 am
CET on July 7, 2016.